Can a low-dose drug wake up the immune system against breast cancer?

NCT ID NCT04891068

Recruiting now Knowledge-focused Sponsor: University of Illinois at Chicago Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is testing whether a low dose of the drug azacitidine, given before surgery, can increase immune cells (called tumor-infiltrating lymphocytes) in the tumors of people with high-risk early-stage breast cancer. About 40 participants will receive the drug for a short time before their planned surgery. The goal is to see if the drug makes the tumor more visible to the immune system, which could lead to better treatment options in the future.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EARLY-STAGE BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm invasive breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER INVASIVE EARLY-STAGE BREAST CANCER HIGH RISK BREAST CARCINOMA

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

University of Illinois Cancer Center
RECRUITING

Chicago, Illinois, 60612, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact Phone: •••-•••-•••• Email: •••••@•••••